Compare AbbVie Inc (ABBV) vs Seagate Technology Holdings PLC (STX) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

STX trades at $812.76, down 4.71% in the last 24 hours, with technical indicators showing a bearish trend and key support at $758. The company reported strong Q2 2026 earnings, beating estimates with EPS of $5.71 versus $5.10 expected, driven by AI storage demand. Valuation ratios are elevated, with a P/E of 58.47 and P/S of 15.26, while profitability remains robust with a net income margin of 26.11%.

Outlook is positive due to AI-driven growth and analyst consensus, but high valuation and competitive pressures pose risks. The consensus price target is $1,130, offering ~39% upside, supported by 28 buy ratings. Investors should weigh strong fundamentals against premium pricing and market volatility.